ArticleCancer cell2011
Resisting targeted therapy: fifty ways to leave your EGFR.
Article in Cancer cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Promise and challenges on the horizon of MET-targeted cancer therapeutics.World journal of biological chemistry · 2015Article
- Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.Expert review of molecular diagnostics · 2015Review
- An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Nature cell biology · 2014Article
- Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2014Review
- Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.PloS one · 2014Article
- Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Frontiers in oncology · 2013Review
- Return of the malingering mutants.British journal of cancer · 2013Article
- Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.British journal of cancer · 2013Article
- Mechanisms of resistance to EGFR targeted therapies.Cancer biology & therapy · 2013Review
- Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.Clinical pharmacology and therapeutics · 2013Review
- Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Cancer discovery · 2012Article
- The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.Molecular oncology · 2012Review
- Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.Chemotherapy research and practice · 2012Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic workarounds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.